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The cytokine, cachectin/tumor necrosis factor (TNF), was identified originally
on the basis of its abilityto induce hemorrhagic necrosis oftumors andto contribute
to the severe wasting (cachexia) that accompanies chronic parasitic and viral infec-
tions and neoplastic disease . Recently, it has been become clear that TNF is an in-
ducer of shock and a potent pro-inflammatory mediator capable of stimulating in
vitro functions of monocytes, eosinophils, neutrophils, endothelial cells, and fibro-
blasts (1) .
Depending upon the disease model, the effect ofTNF may be either beneficial
or harmful . For example, TNF has been shown (a) to be involved in resistance to
Listeria monocytogenes (2) and Bacillus Calmette Guerin (BCG) t (3), (b) to cause
killing of virus-infected cells (4-6), (c) to be capable of enhancing the cytotoxicity
of both eosinophils (7) and platelets (8) for schistosomes, and (d) to be able to acti-
vate neutrophils to kill Candida albicans (9) and macrophages to kill Trypanosoma cruzi
(10) . In contrast to these beneficial effects, in the case of malarial infection, TNF
seems to be an important mediator of the host-destructive pathogenesis that accom-
panies murine cerebral malaria (11) .
We observed initially that lymph node cells (LNC) from mice infected with, or
sensitized to, the protozoan parasite Leishmania major, could produce, upon stimula-
tion with either parasite antigens or mitogens in vitro, substantial amounts of a sub-
stance that was cytotoxic for L929 cells . We therefore investigated the role ofTNF
in the course ofmurine cutaneous leishmaniasis induced by L. major . This article
shows that C3H mice (resistant to L . major) produced significant amounts of TNF
during the course of infection withL . major. In contrast, TNF production by BALB/c
mice (susceptible to L. major) was never detected . In addition, repeated injection
of recombinant human TNF (rHuTNF) into both strains ofmice infected with L.
major had a therapeutic effect on the course of infection . In contrast, injection of
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a neutralizing anti-murine TNF antibody was shown to markedly exacerbate the




C3H/HeN and BALB/c mice were obtained from Taconic Farms (Germantown,
NY) and were used as sex-matched young adults at 8-10 wk old.
Leishmania major and Infection with L. major.
￿
L. major promastigotes (IV 39) were main-
tained as described (12), and when used, were taken from stationary phasecultures (13). The
numbers ofpromastigotes stated in the text were injected subcutaneously in the hind footpad
and lesion progression was followed by determining the increase in footpad thickness with
a vernier caliper relative to the contralateral uninfected control footpad.
Determination of the Number ofL. major in Infected Mouse Tissues.
￿
Enumeration of L. major
in the infected footpad and draining lymph nodes was performed using a limiting dilution
assay described in detail elsewhere (14).
Productionof TNFby Mouse LNC.
￿
Mice were injected with 5 x 106 L. major promastigotes
subcutaneously in the hind footpads and at intervals during the course ofinfection the popliteal
and inguinal lymph nodes were removed. Single cell suspensions were produced and 4 x
106 LNC/well were cultured in 48-well plates (Costar, Cambridge, MA) containing 0.5 ml
of DME (15) supplemented with 0.5% normal mouse serum. The cultures were stimulated
with either 3 x 104, 105, or 3 x 105 L. major promastigotes/milliliter. At varying times there-
after, the supernatants of the cultures were harvested and stored at -70°C until they were
analyzed for their content of TNF by the L929 cell cytotoxicity assay.
Recombinant Human TNF (rHuTNF).
￿
rHuTNF was kindly provided by Chiron Corp.
(Emeryville, CA) and exhibited a specific activity of 2 x 108 U/mg.
Purification ofNative Murine TNF (mTNF).
￿
The mouse macrophage cell line RAW 264.7
(American Type Culture Collection, Rockville, MD) was maintained in culture according
to established procedures(16). Using conditioned medium from LPS-stimulated RAW 264.7
cells as the starting material, mTNF for use as a standard and for immunization purposes
was purified to homogeneity in a manner identical to that described previously (17).
Preparation ofNeutralizing Rabbit Anti-Murine TNF(antiTNF)and Normal RabbitIg(nrlg).
￿
Fe-
male New Zealand white rabbits were immunized with mTNF according to a regimen de-
scribed previously (17). An immune Ig fraction pooled from five rabbits (antiTNF) was ob-
tained by ammonium sulfate precipitation according to established procedures (18). The
precipitate was extensively dialyzed, and the protein content was determined by Bradford
assay (19). This antiTNF preparation is not known to react with any cytokines other than TNF
(our unpublished observations) . nrIg was obtained by pooling sera collected from normal




A clone of the fibroblast line L929 (kindly provided by Dr.
A. Glasebrook, Lilly Research Laboratories, LaJolla, CA), selected for its sensitivity to the
cytotoxic effects of TNF, was used. L929 cells were cultured in 96-well plates (Costar, Cam-
bridge, MA) at 2 x 105/well in DME with 5% FCS (Gibco Laboratories, Grand Island, NY).
The cellswere cultured for 36 h at which time, the culture medium was replaced with medium
containing a final concentration of 1 Fig/ml actinomycin D (Sigma Chemical Co., St. Louis,
MO) and various dilutions of test supernatants obtained from the LNC ofinfected mice as
described above. The plates were then cultured overnight, at which time the degree of cyto-
toxicity ofthe supernatants forthe L929 cells was determined by the 3(4,5-dimethyl-thiazoyl-
2-yl)2,5 diphenyltetrazolium bromide (MTT) colorimetric assay for cell viability (20).
The OD obtained with L929 cells cultured with medium alone (negative control) or with
the supernatant of LNC not restimulated with L. major in vitro did not differ significantly.
Therefore, the percent cytotoxicity effected by supernatants containing TNF activity was
calculated using the following formula: percent cytotoxicity = [1 - (OD TNRtreated/OD
negative control)] x 100.
1 U of TNF was defined as the amount of material resulting in 50% cytotoxicity for theL929 monolayers. Thus,bycomparison toa standardcurveobtainedwithdilutions ofpurified
mTNF, the number of units of TNF in each test supernatant could be calculated.
Results
To assess whether there exists a'correlation between resistance to experimental
murine cutaneousleishmaniasis andthe ability ofinfected animals toproduceTNF
inresponse to parasite antigens, C3H (resistant)and BALB/c(susceptible) mice were
infected with L. major, and at intervals thereafter assessed for the capacity of their
LNC to produce TNFin responsetoparasitechallenge. Results in Fig. 1 A demon-
strate that LNC isolated from C3H mice at various time intervals after infection
with L. majorwere able to produce measurable amounts ofTNF when restimulated
with the parasite invitro. The highest TNFlevels were observed in cultures ofLNC
obtained from C3H mice infected with L. major for 63 d (Fig. 1 A), a time when
cutaneouslesionswereessentiallyhealed intheanimals (Fig. 1B). In contrast, BALB/c
LNC were not abletoproducesignificantlevels ofTNF at anytimeduring thecourse
of infection.
The experimentsaboveindicated that the ability ofLNC from mice infectedwith
L. major to produce TNF in vitro in response to challenge with the parasite cor-
related with the resistance ofthe mice to infection with the parasite in vivo. This
suggested that host production ofTNF might have a protective effect on the course
ofcutaneous leishmaniasis. Wetherefore examined theeffects ofinjectingrHuTNF




TNFproduction by LNC isolated from C3HandBALB/c mice infected withL. major.
(A) At the indicated dayof infection, LNC were harvested from duplicate C3H (open bars) and
BALB/c (shaded bars)mice andstimulated in vitrofor 24 hwith 105parasites/ml.Theconcentra-
tion of TNF present in the supernatants of the LNCcultures wasdetermined in the L929 cyto-
toxicity assay (see MaterialsandMethods). The data presented were obtained in triplicate L929
cultures t SD. Similardatawere obtained with otherdosesofparasites andafter48 hofstimula-
tion in vitro. When a culture supernatant displayed cytotoxic activity for L929 cells, the fact
that this wasduestrictly to the presence of TNF in thesupernatant wasconfirmed by including
antiTNF in the culture. In each case, the L929 cytotoxic capacity of apositive supernatant was
completely blockedby a final concentration ofeither 200 or 400Wg/mlof antiTNF (B) Groups
offiveC3H~0)andfive BALB/c (N)mice each were injected subcutaneously in thehind footpad
with 5 x 10 L. majorpromastigotes. The figure depicts the mean increase in the thickness of
theinfected footpad compared with thethicknessofthecontroluninfected footpad (see Materials
and Methods for techniques).2100
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or antiTNFantibodies in both C3H(resistant) and BALB/c (susceptible) mice experimen-
tally infected with L. major. Representative results of three experiments with C3H
mice are presented in Fig. 2. As can be seen, administering rHuTNF impeded le-
sion development (Fig. 2 A) whiletreatment with antiTNF significantly exacerbated
lesion development (Fig. 2 B). Similar results were obtained using BALB/c mice
(Fig. 3 A andB). In experimentsusing antiTNF, groups of mice were also injected
with nrIg, which controlled for any nonspecific effects that might occur due to the
injection of mice with rabbit Ig. Results depicted in Fig. 2 B reveal there was no
difference in lesion development in nrIg-treated and untreated control mice.
The experiments presented above demonstrated that TNF could impede lesion
development in cutaneous leishmaniasis. It therefore became important to deter-
mine whetherthis effect ofTNFon lesion size was accompaniedby aparallel change
in the numbers of L. major parasites in the lesion. If parasite multiplication were
also inhibited by TNF, this would indicate that TNF was protective for the host not
only through control of pathological damage but also by inhibition of parasite repli-
cation. Representative results of three experiments are given in Table I. At day 21
of infection, mice treated with rHuTNF had 12-fold fewer parasites in their lesions
than did controlmice. In contrast, treatment with antiTNFresulted in a 20-fold in-
crease in the number of parasites in the lesions. In addition, at day 39 of infection,
whereas substantial numbers of parasites were still detectable in mice treated with
anti TNF, no parasiteswere detected in control lesionsor in lesionsof mice treated with
nrIg (data not shown). Similar results were obtained when lymph nodes draining







Effect of rHuTNF andaTNF on the course of murine cutaneousleishmaniasis in
C3Hmice. (A)Five C3H mice were injected subcutaneously in onehind footpad with 20 x 106
L. major and were treated with rHuTNF (A) by intravenous injection of 2 Wg rHuTNF on days
7, 10, and 13 of infection; 3,ug rHuTNF on days 16, 19, and 22 of infection; and 4 ug rHuTNF
on days 24, 27, and30 ofinfection. Controlmice (EI) were nottreatedwith rHuTNF.(B)Groups
of five C3H mice each were injected subcutaneously in onehind footpad with 0.5 x 10 L. major
andwere treated with antiTNF(A) or nrIg (/)by intraperitoneal injection of 200,ug ofeither
materialevery2 dbeginningat day7 ofinfection. Controlmice ([]) were challenged with L. major
but were otherwise untreated. Injection of 200 ug dTNF every 2nd day yielded detectable cir-
culatingantiTNFin thetreatedmice when assayed afterfive injections ofanti-TNF Thefigure depicts
themean increase in the thickness of theinfected footpad ( t SE) compared with the thickness






Effect of rHuTNF and otTNF on the course of murine cutaneous leishmaniasis in
BALB/c mice. (A) BALB/c mice challenged with 2 x 106 L. majorand treated with rHuTNF (A);
control mice not treated with rHuTNF (EI). (B) BALB/c mice challenged with 0.5 x 106 L. major
and treated with antiTNF (A); control mice not treated with antiTNF (0). Techniques were
as described in the legend of Fig. 2.
TABLE I
Number of Leishmania major in the Lesions and Lymph Nodes
ofMite Treated with Anti-TNFAntibody or With TNF
Number of L. major
￿





0.5 x 106 L. major
￿
None
0.5 x 106 L. major
￿
nrIg
0.5 x 106 L. major
￿
AntiTNF




1212.0 t 273 .7
￿
10.5 t 3.3







Groups ofC3H mice were treated with anti-TNF, nrIg, or rHuTNF as described
in the legend of Fig. 2. At day 21 of infection, duplicate mice were assessed for
the number of L. major present in the lesions and draining lymph nodes as
described in Materials and Methods.
ofparasitesin thelymph nodes ofmice treated with antiTNF was35-foldhigher than
the number present in mice treated with nrIg (Table I).
Discussion
The role of TNF in immunity in experimental murine cutaneous leishmaniasis
was investigated. We found that whereas LNC from mice genetically susceptible to
infection with L. major (BALB/c) produced little TNF in response to the parasite,
LNC from infected C3H mice (genetically resistant) produced everincreasingquan-
tities ofTNF through the course ofthedisease (Fig. 1 A). It is notknown whyresis-
tant mice produced the greatest amounts ofTNF late in thecourse ofinfection (i.e.,
63 d ofinfection; Fig. 1 A); however, several explanations are possible. Early in the
course ofinfection ofresistant mice with L. major, LNC draining the lesion contain
large numbers of parasites, whereas at later timepoints few parasites can be found
in lesion f SE in LNC t SE
10.2 t 3 .6 9.2 t 2.4
11 .8 t 5 .0 2.3 f 0.6
190.9 t 43 .0 76.5 t 25.82102
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(14). It is possible therefore that at earliertimepoints TNF is consumed by the cul-
tures, whereas as the parasites are cleared from the LNC, excess amounts ofTNF
are produced. Alternatively, since it is not known what cell is producing the TNF
in the LNC cultures (i.e., macrophages orT cells), it is possiblethat parasite-specific
T cells are the major source ofthe TNF. The frequency ofparasite-specific T cells
in lymph nodesdraining thelesion increaseswith the duration ofinfection(21). There-
fore, it is possible that the ability ofthe LNC to produce TNF increases as the fre-
quency of parasite-specific T cells increases.
Sincethe abilityofthehost toproduce TNF inresponse to infection with L. major
correlated with resistance ofthe host to infection, we also investigated the effect of
injectingTNF or aneutralizingantiTNF antibody into mice infectedwith L. major.
Treatment with TNFwasbeneficial for thehostandantiTNFtreatmentwasdetrimental
for the host in both C3H (resistant) and BALB/c (susceptible) mice infected with
the parasite, although the effect was more pronounced in resistant mice (compare
Figs. 2 and 3). In addition, the beneficial/detrimental effect ofTNF or antiTNF on
cutaneous lesions of L. major was accompanied by a decrease or increase, respec-
tively, in the numberofparasitespresentinthe lesions. Taken together, theseresults
suggest that in theL. major-infected host,TNF canbe protective forthe host through
its capacity to inhibit parasite multiplication, and thus reduce damage to the host
resulting from the pathological changes associated with the disease.
The mechanism by which TNF exerts its protective effect on the course ofcuta-
neous leishmaniasis is currently under investigation. To determine whether TNF
has a direct cytotoxic effect on L. major, we have cultured L. major promastigotes
with as much as 1,000 U/ml ofTNF for as long as 10 d. TNF didnot alter the mul-
tiplication rate of the parasites under any condition. Since the macrophage is the
mammalianhost cell forL. major (22) and sinceTNF canexist as atransmembrane
protein inmacrophages (23), wehave also investigated whetherthedetrimentaleffect
ofinjecting antiTNF into mice infected with L. majormightbedue tolysisofinfected
macrophages viacomplement-mediated cytotoxicity. Lysis ofinfected macrophages
could have resulted in rapid dissemination of L. major to uninfected macrophages
andmight also have inhibitedpresentation ofparasiteantigens by macrophages thus
inhibiting thedevelopmentofspecificT cellimmunity. TodeterminewhetherantiTNF
could affect macrophages, we injected mice intraperitoneally every second day for
atotal of 10 dwitheither antiTNFor nrIg and the resident peritoneal cells orspleens
were harvested from both groups ofmice. The cell yields from both groups ofmice
were identical and there were >95% esterase-positive cells (24) in both peritoneal
cellpopulations, suggestingthat injection ofantiTNFhad not depleted macrophages
inthe animals. Inaddition, therewas nodifference in the abilityofspleen cells from
either group ofmice to actas antigen-presenting cells in vitro foran L. major-specific
T cell line. Taken together, these results suggest that the beneficial effect of TNF
on cutaneous leishmaniasis is due to its ability to activate infected macrophages to
destroy L. major or its ability to interact with other cells and lymphokines of the
immune system resulting in enhanced resistance to Leishmania. In fact, prelimi-
nary experiments are revealing that TNF is able to inhibit parasite replication in
macrophages in vitro, which suggests thatthe beneficial effect ofTNFon cutaneous
leishmaniasis may be mediated through its ability to activate macrophages. These
results are similar to those recently reported by Wirth and Kierszenbaum (10) inTITUS ET AL.
￿
2103
which TNF was found to activate macrophages to destroy Trypanosoma cruzi. Thus,
in addition to IFN-y, TNF may activate macrophages to destroy many intracellular
pathogens.
Summary
The ability of mice to resist infection with L. major correlated directly with the
capacity of their LNC to produce TNF in response to in vitro parasite challenge.
Blocking TNF in vivo by passively administering antiTNF antibodies exacerbated
the course of L. major infection, resulting in substantially larger cutaneous lesions
and elevated numbers of parasites within those lesions. In addition, treatment of
infected mice with exogenous rHuTNF afforded host protection as evidenced by smaller
lesion size and decreased parasite counts. Taken together, these results suggest a central
role for TNF in resistance to L. major.
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